Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management

References

• Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2018;40(3):237–269. doi: 10.1093/eurheartj/ehy462
   Web of Science ®Google Scholar
• Capodanno D, Baber U, Bhatt DL, et al. P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nat Rev Cardiol. 2022 Dec 01;19(12):829–844. doi: 10.1038/s41569-022-00725-6
   PubMed Web of Science ®Google Scholar
• Marquis-Gravel G, Dalgaard F, Jones AD, et al. Post-discharge bleeding and mortality following acute coronary syndromes with or without PCI. J Am Coll Cardiol. 2020 Jul 14;76(2):162–171. doi: 10.1016/j.jacc.2020.05.031
   PubMed Web of Science ®Google Scholar
• Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012 Jan 05;366(1):54–63.
   PubMed Web of Science ®Google Scholar
• Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524–533. doi: 10.1038/s41586-021-03392-8
   PubMed Web of Science ®Google Scholar
• Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13–20. doi: 10.1016/S0140-6736(03)12113-7
   PubMed Web of Science ®Google Scholar
• Byrne RA, Stone GW, Ormiston J, et al. Coronary balloon angioplasty, stents, and scaffolds. Lancet. 2017 Aug 19;390(10096):781–792. doi: 10.1016/S0140-6736(17)31927-X
   PubMed Web of Science ®Google Scholar
• Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44(38):3720–3826. doi: 10.1093/eurheartj/ehad191
   PubMed Web of Science ®Google Scholar
• Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart association Joint Committee on clinical practice guidelines. Circulation. 2022;145(3):e18–e114.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Galli M, Collet J-P, et al. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention. 2022;17(17):e1371–e1396. doi: 10.4244/EIJ-D-21-00904
   PubMed Web of Science ®Google Scholar
• Buccheri S, Capodanno D, James S, et al. Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opin Drug Saf. 2019 Dec 02;18(12):1171–1189. doi: 10.1080/14740338.2019.1680637
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019;41(3):407–477. doi: 10.1093/eurheartj/ehz425
   Web of Science ®Google Scholar
• Rodriguez F, Harrington RA, Longo DL. Management of antithrombotic therapy after acute coronary syndromes. N Engl J Med. 2021 Feb 04;384(5):452–460.
   PubMed Web of Science ®Google Scholar
• Galli M, Angiolillo DJ. De-escalation of antiplatelet therapy in acute coronary syndromes: why, how and when? [review]. Front Cardiovasc Med. 2022 Aug 25;9. doi: 10.3389/fcvm.2022.975969
   Google Scholar
• Mazzone PM, Angiolillo DJ, Capodanno D. Approaches to de-escalation of antiplatelet treatment in stabilized post-myocardial infarction patients with high ischemic risk. Expert Rev Cardiovasc Ther. 2022 Oct 03;20(10):839–849.
   PubMed Web of Science ®Google Scholar
• Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase Clinical Findings Through Hospital Discharge. Circulation. 1987;76(1):142–154. doi: 10.1161/01.CIR.76.1.142
   PubMed Web of Science ®Google Scholar
• GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673–682. doi: 10.1056/NEJM199309023291001
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with Prior myocardial infarction. N Engl J Med. 2015 May 07;372(19):1791–1800. doi: 10.1056/NEJMoa1500857
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Bhatt DL, et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation. 2011;123(23):2736–2747. doi: 10.1161/CIRCULATIONAHA.110.009449
   PubMed Web of Science ®Google Scholar
• Quinlan DJ, Eikelboom JW, Goodman SG, et al. Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. Eur Heart J. 2011;32(18):2256–2265. doi: 10.1093/eurheartj/ehr143
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients. J Thromb Haemost. 2005 Apr 01;3(4):692–694.
   PubMed Web of Science ®Google Scholar
• Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working group on thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32(15):1854–1864. doi: 10.1093/eurheartj/ehr204
   PubMed Web of Science ®Google Scholar
• Rao SV, O’Grady K, Pieper KS, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006 Feb 21;47(4):809–816. doi: 10.1016/j.jacc.2005.09.060
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) randomized trial. Eur Heart J. 2017;38(11):804–810. doi: 10.1093/eurheartj/ehw525
   PubMed Web of Science ®Google Scholar
• Vranckx P, White HD, Huang Z, et al. Validation of BARC bleeding criteria in patients with acute coronary syndromes: the TRACER trial. J Am Coll Cardiol. 2016 May 10;67(18):2135–2144. doi: 10.1016/j.jacc.2016.02.056
   PubMed Web of Science ®Google Scholar
• Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non–ST-Segment–elevation myocardial infarction. Circulation. 2009;119(14):1873–1882. doi: 10.1161/CIRCULATIONAHA.108.828541
   PubMed Web of Science ®Google Scholar
• Wang TKM, Mehta OH, Liao Y-W, et al. Meta-analysis of bleeding scores performance for acute coronary syndrome. Heart Lung & Circulation. 2020;29(12):1749–1757. doi: 10.1016/j.hlc.2020.04.008
   PubMed Web of Science ®Google Scholar
• Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010 Jun 08;55(23):2556–2566. doi: 10.1016/j.jacc.2009.09.076
   PubMed Web of Science ®Google Scholar
• Simonsson M, Winell H, Olsson H, et al. Development and validation of a novel risk score for in‐hospital major bleeding in acute myocardial infarction: —the SWEDEHEART score. J Am Heart Assoc. 2019;8(5). doi: 10.1161/JAHA.119.012157
   PubMed Web of Science ®Google Scholar
• Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025–1034. doi: 10.1016/S0140-6736(17)30397-5
   PubMed Web of Science ®Google Scholar
• Raposeiras-Roubín S, Faxén J, Íñiguez-Romo A, et al. Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: the BleeMACS score. Int J Cardiol. 2018;254:10–15. doi: 10.1016/j.ijcard.2017.10.103
   PubMed Web of Science ®Google Scholar
• Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019 Jul 16;140(3):240–261. doi: 10.1161/CIRCULATIONAHA.119.040167
   PubMed Web of Science ®Google Scholar
• Yasushi U, Sarah B, Sylvain L, et al. Validation of the Academic research Consortium for high bleeding risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention. 2020;16(5):371–379. doi: 10.4244/EIJ-D-20-00052
   PubMed Web of Science ®Google Scholar
• Corpataux N, Spirito A, Gragnano F, et al. Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. Eur Heart J. 2020;41(38):3743–3749. doi: 10.1093/eurheartj/ehaa671
   PubMed Web of Science ®Google Scholar
• Baber U, Mehran R, Giustino G, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol. 2016 May 17;67(19):2224–2234. doi: 10.1016/j.jacc.2016.02.064
   PubMed Web of Science ®Google Scholar
• Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315(16):1735–1749. doi: 10.1001/jama.2016.3775
   PubMed Web of Science ®Google Scholar
• Urban P, Gregson J, Owen R, et al. Assessing the risks of bleeding vs thrombotic events in patients at high bleeding risk after coronary stent implantation: the ARC–high bleeding risk trade-off model. JAMA Cardiol. 2021;6(4):410–419. doi: 10.1001/jamacardio.2020.6814
   PubMed Web of Science ®Google Scholar
• Capodanno D, Bhatt DL, Gibson CM, et al. Bleeding avoidance strategies in percutaneous coronary intervention. Nat Rev Cardiol. 2022 Feb 01;19(2):117–132. doi: 10.1038/s41569-021-00598-1
   PubMed Web of Science ®Google Scholar
• Siontis GCM, Mavridis D, Greenwood JP, et al. Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials. BMJ. 2018;360:k504. doi: 10.1136/bmj.k504
   PubMedGoogle Scholar
• Spagnolo M, Greco A, Laudani C, et al. Impact of the ISCHEMIA trial on the role of noninvasive diagnostic pathways in patients with chronic coronary syndrome. J Cardiovasc Comput Tomogr. 2023;17(3):236–238. doi: 10.1016/j.jcct.2023.03.005
   PubMed Web of Science ®Google Scholar
• Boden William E, Marzilli M, Crea F, et al. Evolving management paradigm for stable ischemic Heart disease patients. J Am Coll Cardiol. 2023 Feb 07;81(5):505–514. doi: 10.1016/j.jacc.2022.08.814
   PubMedGoogle Scholar
• Hamilton-Craig C, Fifoot A, Hansen M, et al. Diagnostic performance and cost of CT angiography versus stress ECG — a randomized prospective study of suspected acute coronary syndrome chest pain in the emergency department (CT-COMPARE). Int J Cardiol. 2014;177(3):867–873. doi: 10.1016/j.ijcard.2014.10.090
   PubMed Web of Science ®Google Scholar
• Levsky JM, Spevack DM, Travin MI, et al. Coronary computed tomography angiography versus radionuclide myocardial perfusion imaging in patients with chest pain admitted to telemetry. Ann internal med. 2015 Aug 04;163(3):174–183. doi: 10.7326/M14-2948
   PubMed Web of Science ®Google Scholar
• Piñeiro-Portela M, Peteiro-Vázquez J, Bouzas-Mosquera A, et al. Comparison of two strategies in a chest pain unit: stress echocardiography and multidetector computed tomography. Revista Española de Cardiología (English Edition). 2021 Jan 01;74(1):59–64. doi: 10.1016/j.rec.2020.01.023
   PubMed Web of Science ®Google Scholar
• Capodanno D, Angiolillo Dominick J. Timing, selection, modulation, and duration of P2Y12 inhibitors for patients with acute coronary syndromes undergoing PCI. JACC Cardiovasc Interv. 2023 Jan 09;16(1):1–18.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Angiolillo DJ. Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era. Circ Cardiovasc Interventions. 2015 Mar 01;8(3):e002301.
   PubMed Web of Science ®Google Scholar
• Bellemain-Appaix A, Kerneis M, O’Connor SA, et al. Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ: British Med J. 2014;349:g6269. doi: 10.1136/bmj.g6269
   Web of Science ®Google Scholar
• Bellemain-Appaix A, Begue C, Bhatt LD, et al. The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis. EuroIntervention. 2018;14(1):78–85. doi: 10.4244/EIJ-D-17-00852
   PubMed Web of Science ®Google Scholar
• Greco A, Laudani C, Rochira C, et al. Antithrombotic management in AF patients following percutaneous coronary intervention: a European perspective. Interventional Cardiol. 2023;18:e05. doi: 10.15420/icr.2021.30
   PubMedGoogle Scholar
• Kumbhani Dharam J, Cannon Christopher P, Beavers Craig J, et al. 2020 ACC Expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2021 Feb 09;77(5):629–658. doi: 10.1016/j.jacc.2020.09.011
   PubMed Web of Science ®Google Scholar
• Lip GYH, Collet J-P, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm association (EHRA), European Society of Cardiology Working group on thrombosis European Association Of Percutaneous Cardiovascular Interventions (EAPCI), And European Association Of Acute Cardiac Care (ACCA) Endorsed By The Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), And Cardiac Arrhythmia Society Of Southern Africa (CASSA). EP Europace. 2019;21(2):192–193.
   PubMed Web of Science ®Google Scholar
• Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021;23(10):1612–1676. doi: 10.1093/europace/euab065
   PubMed Web of Science ®Google Scholar
• Mason PJ, Shah B, Tamis-Holland JE, et al. An update on radial artery access and best practices for transradial coronary angiography and intervention in acute coronary syndrome: a scientific statement from the American Heart association. Circ Cardiovasc Interventions. 2018 Sep 01;11(9):e000035. doi: 10.1161/HCV.0000000000000035
   PubMed Web of Science ®Google Scholar
• Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011 Apr 23;377(9775):1409–1420. doi: 10.1016/S0140-6736(11)60404-2
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Gagnor A, Calabró P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015 Jun 20;385(9986):2465–2476. doi: 10.1016/S0140-6736(15)60292-6
   PubMed Web of Science ®Google Scholar
• Andò G, Capodanno D. Radial versus femoral access in invasively managed patients with acute coronary syndrome. Ann internal med. 2015 Dec 15;163(12):932–940.
   PubMed Web of Science ®Google Scholar
• Chiarito M, Cao D, Nicolas J, et al. Radial versus femoral access for coronary interventions: an updated systematic review and meta-analysis of randomized trials. Catheter Cardiovasc Interv. 2021;97(7):1387–1396. doi: 10.1002/ccd.29486
   PubMed Web of Science ®Google Scholar
• Gragnano F, Jolly Sanjit S, Mehta Shamir R, et al. Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score. EuroIntervention. 2021;17(12):e971–e980. doi: 10.4244/EIJ-D-21-00441
   PubMed Web of Science ®Google Scholar
• Sorrentino S, Nguyen P, Salerno N, et al. Standard versus ultrasound-guided cannulation of the femoral artery in patients undergoing invasive procedures: a meta-analysis of randomized controlled trials. J Clin Med. 2020;9(3):677. doi: 10.3390/jcm9030677
   PubMed Web of Science ®Google Scholar
• Entremont M-A, Alrashidi S, Alansari O, et al. Ultrasound-guided femoral access in patients with vascular closure devices: a prespecified analysis of the randomised UNIVERSAL trial. EuroIntervention. 2023;19(1):73–79. doi: 10.4244/EIJ-D-22-01130
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SRC, Susan Afzal R, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-Segment elevation myocardial InfarctionThe OASIS-6 randomized trial. JAMA. 2006;295(13):1519–1530.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta S, Chrolavicius S, et al. Comparison of Fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464–1476.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Toklu B, Kotwal A, et al. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. BMJ: British Med J. 2014;349(nov11 4):g6419. doi: 10.1136/bmj.g6419
   Google Scholar
• Navarese EP, De Luca G, Castriota F, et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost. 2011 Oct 01;9(10):1902–1915. doi: 10.1111/j.1538-7836.2011.04445.x
   PubMed Web of Science ®Google Scholar
• Silvain J, Beygui F, Barthélémy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012;344(feb03 1):e553. doi: 10.1136/bmj.e553
   PubMedGoogle Scholar
• Drouet L, Bal Dit Sollier C, Martin J. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study. Am Heart J. 2009 Aug 01;158(2):177–184.
   PubMed Web of Science ®Google Scholar
• Cohen M, Mahaffey KW, Pieper K, et al. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non–ST-Segment elevation acute coronary syndromes. J Am Coll Cardiol. 2006 Oct 03;48(7):1346–1354. doi: 10.1016/j.jacc.2006.05.058
   PubMed Web of Science ®Google Scholar
• Capodanno D, Gargiulo G, Capranzano P, et al. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: an updated meta-analysis of 10,350 patients from five randomized clinical trials. Eur Heart J Acute Cardiovasc Care. 2016;5(3):253–262. doi: 10.1177/2048872615572599
   PubMed Web of Science ®Google Scholar
• Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet. 2014;384(9943):599–606. doi: 10.1016/S0140-6736(14)61216-2
   PubMed Web of Science ®Google Scholar
• Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med. 2017 Sep 21;377(12):1132–1142. doi: 10.1056/NEJMoa1706443
   PubMed Web of Science ®Google Scholar
• Li Y, Liang Z, Qin L, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Lancet. 2022 Nov 26;400(10366):1847–1857. doi: 10.1016/S0140-6736(22)01999-7
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045–1057. doi: 10.1056/NEJMoa0904327
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001–2015. doi: 10.1056/NEJMoa0706482
   PubMed Web of Science ®Google Scholar
• Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020;395(10233):1374–1381. doi: 10.1016/S0140-6736(20)30325-1
   PubMed Web of Science ®Google Scholar
• Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009 Dec 10;361(24):2318–2329. doi: 10.1056/NEJMoa0908628
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009 Dec 10;361(24):2330–2341. doi: 10.1056/NEJMoa0908629
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013 Dec 14;382(9909):1981–1992. doi: 10.1016/S0140-6736(13)61615-3
   PubMed Web of Science ®Google Scholar
• Winchester DE, Wen X, Brearley WD, et al. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. J Am Coll Cardiol. 2011 Mar 08;57(10):1190–1199. doi: 10.1016/j.jacc.2010.10.030
   PubMed Web of Science ®Google Scholar
• Piccolo R, Bonaa KH, Efthimiou O, et al. Individual patient data meta-analysis of drug-eluting versus Bare-metal stents for percutaneous coronary intervention in chronic versus acute coronary syndromes. Am J Cardiol. 2022 Nov 01;182:8–16.
   PubMed Web of Science ®Google Scholar
• Greco A, Capodanno D. Differences in coronary artery disease and outcomes of percutaneous coronary intervention with drug-eluting stents in women and men. Expert Rev Cardiovasc Ther. 2021 Apr 03;19(4):301–312.
   PubMed Web of Science ®Google Scholar
• Picard F, Doucet S, Asgar AW. Contemporary use of drug-coated balloons in coronary artery disease: where are we now? Arch Cardiovasc Dis. 2017 Apr 01;110(4):259–272.
   PubMed Web of Science ®Google Scholar
• Kleber F-X, Mathey D, Rittger H, et al. How to use the drug-eluting balloon: recommendations by the German consensus group. EuroIntervention. 2011;7(K):K125–K128. doi: 10.4244/EIJV7SKA21
   PubMed Web of Science ®Google Scholar
• Kleber FX, Rittger H, Bonaventura K, et al. Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. Clin Res Cardiol. 2013 Nov 01;102(11):785–797. doi: 10.1007/s00392-013-0609-7
   PubMed Web of Science ®Google Scholar
• Rissanen TT, Uskela S, Eränen J, et al. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. Lancet. 2019;394(10194):230–239. doi: 10.1016/S0140-6736(19)31126-2
   PubMed Web of Science ®Google Scholar
• Scheller B, Ohlow M-A, Ewen S, et al. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. EuroIntervention. 2020;15(17):1527–1533. doi: 10.4244/EIJ-D-19-00723
   PubMed Web of Science ®Google Scholar
• Capodanno D, Greco A. Dual antiplatelet therapy in patients at high bleeding risk: less is more—more or less. Eur Heart J. 2022;44(11):969–971. doi: 10.1093/eurheartj/ehac713
   Web of Science ®Google Scholar
• Capodanno D, Mehran R, Krucoff MW, et al. Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the Academic research Consortium. Circulation. 2023;147(25):1933–1944. doi: 10.1161/CIRCULATIONAHA.123.064473
   PubMed Web of Science ®Google Scholar
• Kim B-K, Hong M-K, Shin D-H, et al. A New strategy for discontinuation of dual antiplatelet therapy: the RESET trial (REal safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012 Oct 09;60(15):1340–1348. doi: 10.1016/j.jacc.2012.06.043
   PubMed Web of Science ®Google Scholar
• Lohaus R, Michel J, Mayer K, et al. Six versus twelve months clopidogrel therapy after drug-eluting stenting in patients with acute coronary syndrome: an ISAR-SAFE study subgroup analysis. Sci Rep. 2016 Sep 14;6(1):33054. doi: 10.1038/srep33054
   PubMedGoogle Scholar
• Didier R, Morice MC, Barragan P, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: final results of the ITALIC trial (is there a life for DES after discontinuation of clopidogrel). JACC Cardiovasc Interv. 2017 Jun 26;10(12):1202–1210. doi: 10.1016/j.jcin.2017.03.049
   PubMed Web of Science ®Google Scholar
• Kedhi E, Fabris E, van der Ent M, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ. 2018;363:k3793. doi: 10.1136/bmj.k3793
   PubMed Web of Science ®Google Scholar
• Hahn J-Y, Song YB, Oh J-H, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018 Mar 31;391(10127):1274–1284. doi: 10.1016/S0140-6736(18)30493-8
   PubMed Web of Science ®Google Scholar
• Hahn J-Y, Song YB, Oh J-H, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention. JAMA. 2019;321(24):2428. doi: 10.1001/jama.2019.8146
   PubMed Web of Science ®Google Scholar
• Tomaniak M, Chichareon P, Onuma Y, et al. Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes. JAMA Cardiol. 2019;4(11):1092. doi: 10.1001/jamacardio.2019.3355
   PubMed Web of Science ®Google Scholar
• Baber U, Dangas G, Angiolillo DJ, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020;41(37):3533–3545. doi: 10.1093/eurheartj/ehaa670
   PubMed Web of Science ®Google Scholar
• Kim B-K, Hong S-J, Cho Y-H, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with Acute coronary syndrome. JAMA. 2020;323(23):2407. doi: 10.1001/jama.2020.7580
   PubMed Web of Science ®Google Scholar
• Watanabe H, Morimoto T, Natsuaki M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome. JAMA Cardiol. 2022;7(4):407. doi: 10.1001/jamacardio.2021.5244
   PubMed Web of Science ®Google Scholar
• Hong S-J, Lee S-J, Suh Y, et al. Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial. Circulation. 2023. doi: 10.1161/CIRCULATIONAHA.123.066943
   Google Scholar
• Khan SU, Singh M, Valavoor S, et al. Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents. Circulation. 2020;142(15):1425–1436. doi: 10.1161/CIRCULATIONAHA.120.046308
   PubMed Web of Science ®Google Scholar
• Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016 Oct 22;388(10055):2015–2022. doi: 10.1016/S0140-6736(16)31323-X
   PubMed Web of Science ®Google Scholar
• Carrabba N, Parodi G, Marcucci R, et al. Bleeding events and maintenance dose of prasugrel: BLESS pilot study. Open Heart. 2016;3(2):e000460. doi: 10.1136/openhrt-2016-000460
   PubMedGoogle Scholar
• Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38(41):3070–3078. doi: 10.1093/eurheartj/ehx175
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017 Oct 14;390(10104):1747–1757. doi: 10.1016/S0140-6736(17)32155-4
   PubMed Web of Science ®Google Scholar
• Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621–1631. doi: 10.1056/NEJMoa1907096
   PubMed Web of Science ®Google Scholar
• Kim H-S, Kang J, Hwang D, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020 Oct 10;396(10257):1079–1089. doi: 10.1016/S0140-6736(20)31791-8
   PubMed Web of Science ®Google Scholar
• Jin C-D, Kim M-H, Song K, et al. Pharmacodynamics and outcomes of a De-escalation strategy with Half-dose prasugrel or ticagrelor in East Asians patients with acute coronary syndrome: results from HOPE-TAILOR trial. J Clin Med. 2021;10(12):2699. doi: 10.3390/jcm10122699
   PubMed Web of Science ®Google Scholar
• Kim CJ, Park M-W, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021 Oct 09;398(10308):1305–1316. doi: 10.1016/S0140-6736(21)01445-8
   PubMed Web of Science ®Google Scholar
• Galli M, Benenati S, Capodanno D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet. 2021;397(10283):1470–1483. doi: 10.1016/S0140-6736(21)00533-X
   PubMed Web of Science ®Google Scholar
• Laudani C, Greco A, Occhipinti G, et al. Short duration of DAPT versus De-escalation after percutaneous coronary intervention for acute coronary syndromes. JACC Cardiovasc Interv. 2022 Feb 14;15(3):268–277. doi: 10.1016/j.jcin.2021.11.028
   PubMed Web of Science ®Google Scholar
• Capodanno D, Bhatt DL, Eikelboom JW, et al. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Rev Cardiol. 2020 Apr 01;17(4):242–257. doi: 10.1038/s41569-019-0314-y
   PubMed Web of Science ®Google Scholar
• Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107–1115. doi: 10.1016/S0140-6736(12)62177-1
   PubMed Web of Science ®Google Scholar
• Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015 Apr 28;65(16):1619–1629. doi: 10.1016/j.jacc.2015.02.050
   PubMed Web of Science ®Google Scholar
• Oldgren J, Steg PG, Hohnloser SH, et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019;40(19):1553–1562. doi: 10.1093/eurheartj/ehz059
   PubMed Web of Science ®Google Scholar
• Windecker S, Lopes RD, Massaro T, et al. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention. Circulation. 2019;140(23):1921–1932. doi: 10.1161/CIRCULATIONAHA.119.043308
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. Eur Heart J. 2020;41(47):4497–4504. doi: 10.1093/eurheartj/ehaa617
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation. 2021;143(6):583–596. doi: 10.1161/CIRCULATIONAHA.120.050438
   PubMed Web of Science ®Google Scholar
• Agnello F, Finocchiaro S, Laudani C, et al. A review of polypills for the prevention of atherosclerotic cardiovascular disease. Am Heart J. 2023 Aug 26;266:74–85.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Angiolillo DJ. Antithrombotic therapy in the elderly. J Am Coll Cardiol. 2010;56(21):1683–1692. doi: 10.1016/j.jacc.2010.04.063
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Hong M-K, Palmerini T, et al. Short-term versus long-term dual antiplatelet therapy after drug-eluting stent implantation in elderly patients: a meta-analysis of individual participant data from 6 randomized trials. JACC Cardiovasc Interv. 2018 Mar 12;11(5):435–443. doi: 10.1016/j.jcin.2017.10.015
   PubMed Web of Science ®Google Scholar
• Goldsmith DJA, Covic A. Coronary artery disease in uremia: etiology, diagnosis, and therapy. Kidney Int. 2001 Dec 01;60(6):2059–2078.
   PubMed Web of Science ®Google Scholar
• Hwang D, Park KW, Lee JM, et al. Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease. Am Heart J. 2018 Mar 01;197:103–112.
   PubMed Web of Science ®Google Scholar
• Gevaert SA, Halvorsen S, Sinnaeve PR, et al. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a consensus document of the acute CardioVascular care (ACVC) association and the ESC council of cardio-Oncology—Part 1: acute coronary syndromes and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care. 2021;10(8):947–959. doi: 10.1093/ehjacc/zuab056
   PubMed Web of Science ®Google Scholar
• Ko DT, Yun L, Wijeysundera HC, et al. Incidence, predictors, and prognostic implications of hospitalization for late bleeding after percutaneous coronary intervention for patients older than 65 years. Circ Cardiovasc Interventions. 2010;3(2):140–147. doi: 10.1161/CIRCINTERVENTIONS.109.928721
   PubMed Web of Science ®Google Scholar
• Roe MT, Cyr DD, Eckart D, et al. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. Eur Heart J. 2015;37(4):412–422. doi: 10.1093/eurheartj/ehv611
   PubMed Web of Science ®Google Scholar
• Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol. 2020;76(5):594–622. doi: 10.1016/j.jacc.2020.04.053
   PubMed Web of Science ®Google Scholar
• Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart association/American stroke association. Stroke. 2022;53(7):e282–e361. doi: 10.1161/STR.0000000000000407
   PubMed Web of Science ®Google Scholar
• Rao SV. The conundrum of reducing ischemic and bleeding events after PCI. J Am Coll Cardiol. 2015;65(14):1421–1423. doi: 10.1016/j.jacc.2015.02.012
   PubMed Web of Science ®Google Scholar
• Bassand J-P. Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm†. Eur Heart J. 2007;28(11):1273–1274. doi: 10.1093/eurheartj/ehm132
   PubMed Web of Science ®Google Scholar
• Cannon JW, Longo DL. Hemorrhagic shock. N Engl J Med. 2018;378(4):370–379. doi: 10.1056/NEJMra1705649
   PubMed Web of Science ®Google Scholar
• Freynhofer MK, Gruber SC, Grove EL, et al. Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. Thromb Haemost. 2017 Nov 21;114(9):459–468. doi: 10.1160/TH15-02-0179
   Google Scholar
• Torrado J, Buckley L, Durán A, et al. Restenosis, stent thrombosis, and bleeding complications: navigating between scylla and Charybdis. J Am Coll Cardiol. 2018 Apr 17;71(15):1676–1695. doi: 10.1016/j.jacc.2018.02.023
   PubMed Web of Science ®Google Scholar
• Kwok CS, Sherwood MW, Watson SM, et al. Blood transfusion after percutaneous coronary intervention and risk of subsequent adverse outcomes: a systematic review and meta-analysis. JACC Cardiovasc Interv. 2015 Mar 01;8(3):436–446. doi: 10.1016/j.jcin.2014.09.026
   PubMed Web of Science ®Google Scholar
• Bassand JP. Acute coronary syndromes and percutaneous coronary interventions. Impact of bleeding and blood transfusion 2017. Hämostaseologie. 2009 Dec 29;29(4):381–387.
   PubMed Web of Science ®Google Scholar
• Garraud O, Tariket S, Sut C, et al. Transfusion as an inflammation hit: knowns and unknowns [review]. Front Immunol. 2016 Nov 29;7. doi: 10.3389/fimmu.2016.00534
   PubMed Web of Science ®Google Scholar
• Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013;382(9906):1714–1722. doi: 10.1016/S0140-6736(13)61720-1
   PubMed Web of Science ®Google Scholar
• Kazi DS, Leong TK, Chang TI, et al. Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention. J Am Coll Cardiol. 2015 Apr 14;65(14):1411–1420. doi: 10.1016/j.jacc.2015.01.047
   PubMed Web of Science ®Google Scholar
• de Winter MA, Dorresteijn JAN, Ageno W, et al. Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a New risk score. Thromb Haemost. 2021 Sep 20;122(5):818–829. doi: 10.1055/s-0041-1735251
   PubMedGoogle Scholar
• Kwaan HC, Huyck T. Thromboembolic and bleeding complications in acute leukemia. Exp Rev Hematol. 2010 Dec 01;3(6):719–730.
   PubMed Web of Science ®Google Scholar
• Dutton RP. Haemostatic resuscitation. Br J Anaesth. 2012;109(suppl_1):i39–i46. doi: 10.1093/bja/aes389
   PubMedGoogle Scholar
• Dutton RP, Mackenzie CF, Scalea TM. Hypotensive resuscitation during active hemorrhage: impact on in-hospital mortality. J Trauma Acute Care Surg. 2002;52(6):1141–1146. doi: 10.1097/00005373-200206000-00020
   Web of Science ®Google Scholar
• Carrick MM, Morrison CA, Tapia NM, et al. Intraoperative hypotensive resuscitation for patients undergoing laparotomy or thoracotomy for trauma: early termination of a randomized prospective clinical trial. J Trauma Acute Care Surg. 2016;80(6):886–896. doi: 10.1097/TA.0000000000001044
   PubMed Web of Science ®Google Scholar
• Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355–2365. doi: 10.1056/NEJMoa1214609
   PubMed Web of Science ®Google Scholar
• Hisatomi A, Emma H, Candice D, et al. Optimal achieved blood pressure in acute intracerebral hemorrhage. Neurology. 2015;84(5):464. doi: 10.1212/WNL.0000000000001205
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375(11):1033–1043. doi: 10.1056/NEJMoa1603460
   PubMed Web of Science ®Google Scholar
• Cooper HA, Rao SV, Greenberg MD, et al. Conservative versus liberal red Cell transfusion in acute myocardial infarction (the CRIT randomized pilot study). Am J Cardiol. 2011;108(8):1108–1111. doi: 10.1016/j.amjcard.2011.06.014
   PubMed Web of Science ®Google Scholar
• Carson JL, Brooks MM, Abbott JD, et al. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J. 2013 Jun 01;165(6):964–971.e1. doi: 10.1016/j.ahj.2013.03.001
   PubMed Web of Science ®Google Scholar
• Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016;316(19):2025–2035. doi: 10.1001/jama.2016.9185
   PubMed Web of Science ®Google Scholar
• Galli M, Angiolillo DJ. The evaluation and management of coagulopathies in the intensive therapy units. Eur Heart J Acute Cardiovasc Care. 2023;12(6):399–407. doi: 10.1093/ehjacc/zuad051
   PubMed Web of Science ®Google Scholar
• Halvorsen S, Storey RF, Rocca B, et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working group on thrombosis. Eur Heart J. 2016;38(19):1455–1462. doi: 10.1093/eurheartj/ehw454
   Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European association for Cardio-Thoracic surgery (EACTS). Eur Heart J. 2017;39(3):213–260.
   Web of Science ®Google Scholar
• Zhang S, Xu K, Mei L, et al. Reversal of the antiplatelet effect of ticagrelor by simulated platelet transfusion. Transfusion. 2019;59(5):1850–1856. doi: 10.1111/trf.15219
   PubMed Web of Science ®Google Scholar
• Li C, Hirsh J, Xie C, et al. Reversal of the anti‐platelet effects of aspirin and clopidogrel. J Thromb Haemost. 2012;10(4):521–528. doi: 10.1111/j.1538-7836.2012.04641.x
   PubMed Web of Science ®Google Scholar
• Généreux P, Giustino G, Witzenbichler B, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 2015 Sep 01;66(9):1036–1045. doi: 10.1016/j.jacc.2015.06.1323
   PubMed Web of Science ®Google Scholar
• Lanas A, Dumonceau J-M, Hunt RH, et al. Non-variceal upper gastrointestinal bleeding. Nat Rev Dis Primers. 2018 Apr 19;4(1):18020. doi: 10.1038/nrdp.2018.20
   PubMedGoogle Scholar
• Kanno T, Yuan Y, Tse F, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2022;2022(1):1. doi: 10.1002/14651858.CD005415.pub4
   Google Scholar
• Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-Analyses of randomized controlled trials. Clin Gastroenterol Hepatol. 2009 Jan 01;7(1):33–47.
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of gastrointestinal Endoscopy (ESGE) guideline – update 2021. Endoscopy. 2021 Feb 10;53(3):300–332. doi: 10.1055/a-1369-5274
   PubMedGoogle Scholar
• Hansson EC, Shams Hakimi C, Åström-Olsson K, et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth. 2014 Mar 01;112(3):570–575. doi: 10.1093/bja/aet339
   PubMed Web of Science ®Google Scholar
• O’Connor SA, Amour J, Mercadier A, et al. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor. Circ Cardiovasc Interventions. 2015;8(11):e002786. doi: 10.1161/CIRCINTERVENTIONS.115.002786
   PubMed Web of Science ®Google Scholar
• Ortega-Paz L, Giordano S, Franchi F, et al. Clinical and pre-clinical pharmacokinetics and pharmacodynamics of Bentracimab. Clin Pharmacokinet. 2023 May 01;62(5):673–692. doi: 10.1007/s40262-023-01245-3
   PubMedGoogle Scholar
• Baharoglu MI, Cordonnier C, Salman R-S, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016 Jun 25;387(10038):2605–2613. doi: 10.1016/S0140-6736(16)30392-0
   PubMed Web of Science ®Google Scholar
• Colucci G, Stutz M, Rochat S, et al. The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects. Blood. 2014;123(12):1905–1916. doi: 10.1182/blood-2013-04-497123
   PubMed Web of Science ®Google Scholar
• Desborough MJR, Oakland KA, Landoni G, et al. Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2017;15(2):263–272. doi: 10.1111/jth.13576
   PubMed Web of Science ®Google Scholar
• Teng R, Mitchell PD, Butler K. The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. J Clin Pharm Therapeutics. 2014;39(2):186–191. doi: 10.1111/jcpt.12130
   PubMed Web of Science ®Google Scholar
• Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. N Engl J Med. 2017;377(5):431–441. doi: 10.1056/NEJMoa1707278
   PubMed Web of Science ®Google Scholar
• Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor xa. Nature Med. 2013 Apr 01;19(4):446–451. doi: 10.1038/nm.3102
   PubMed Web of Science ®Google Scholar
• Milling TJ, Middeldorp S, Xu L, et al. Final study report of Andexanet alfa for major bleeding with factor xa inhibitors. Circulation. 2023;147(13):1026–1038. doi: 10.1161/CIRCULATIONAHA.121.057844
   PubMed Web of Science ®Google Scholar
• Piccolo R, Calabrò P, Varricchio A, et al. Rationale and design of the PARTHENOPE trial: a two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCI. Am Heart J. 2023 Nov 01;265:153–160.
   PubMed Web of Science ®Google Scholar
• Han Y. Extended clopidogrel monotherapy versus DAPT in high-risk patients: the OPT-BIRISK trial. Presented At: European Society Of Cardiology Congress. 2023 Aug 28.
   Google Scholar
• Guimarães Patricia O, Franken M, Tavares Caio AM, et al. P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET trial. EuroIntervention. 2023;19:e–e. doi: 10.4244/EIJ-D-23-00125
   Web of Science ®Google Scholar
• Natsuaki M, Watanabe H. ShorT and OPtimal duration of dual AntiPlatelet therapy study after everolimus-eluting cobalt-chromium stent-3. Presented At: European Society Of Cardiology CongressAugust 27. 2023.
   Google Scholar
• Greco A, Laudani C, Spagnolo M, et al. Pharmacology and clinical development of factor XI inhibitors. Circulation. 2023;147(11):897–913. doi: 10.1161/CIRCULATIONAHA.122.062353
   PubMed Web of Science ®Google Scholar
• Galli M, Laborante R, Ortega-Paz L, et al. Factor XI inhibitors in early clinical trials: a meta-analysis. Thromb Haemost. 2023 Mar 24;123(6):576–584. doi: 10.1055/a-2043-0346
   PubMedGoogle Scholar
• Gong X, Hua R, Bai J, et al. Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTithrombotic agents (OPTIMA)-4 trial. Clin Cardiol. 2023;46(7):777–784. doi: 10.1002/clc.24025
   PubMedGoogle Scholar
• Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med. 2019;380(19):1825–1833. doi: 10.1056/NEJMoa1901778
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Pollack CV, Mazer CD, et al. Bentracimab for ticagrelor reversal in patients undergoing urgent surgery. NEJM Evi. 2022;1(3):EVIDoa2100047. doi: 10.1056/EVIDoa2100047
   Google Scholar
• Ansell J, Laulicht BE, Bakhru SH, et al. Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants. Blood. 2021 Jan 07;137(1):115–125. doi: 10.1182/blood.2020007116
   PubMed Web of Science ®Google Scholar
• Yang J, Shan D, Wang X, et al. On-site computed tomography–derived fractional flow reserve to guide management of patients with stable coronary artery disease: the TARGET randomized trial. Circulation. 2023;147(18):1369–1381. doi: 10.1161/CIRCULATIONAHA.123.063996
   PubMed Web of Science ®Google Scholar
• Beyar R, Davies EJ, Cook MC, et al. Robotics, imaging, and artificial intelligence in the catheterisation laboratory. EuroIntervention. 2021;17(7):537–549. doi: 10.4244/EIJ-D-21-00145
   PubMed Web of Science ®Google Scholar
• Galli M, Benenati S, Franchi F, et al. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. Eur Heart J. 2021;43(10):959–967. doi: 10.1093/eurheartj/ehab836
   Web of Science ®Google Scholar
• Angiolillo DJ, Capodanno D, Danchin N, et al. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score. JACC Cardiovasc Interv. 2020 Mar 09;13(5):606–617. doi: 10.1016/j.jcin.2020.01.226
   PubMed Web of Science ®Google Scholar
• Galli M, Ortega-Paz L, Franchi F, et al. Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention. Pharmacogenomics. 2022;23(13):723–737. doi: 10.2217/pgs-2022-0057
   PubMed Web of Science ®Google Scholar
• Zhao X, Ma S, Kang Y, et al. Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J Cardiovasc Pharmacother. 2022;8(8):806–814. doi: 10.1093/ehjcvp/pvac026
   PubMed Web of Science ®Google Scholar
• Milluzzo RP, Franchina GA, Capodanno D, et al. Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development. Expert Opin Investig Drugs. 2020 Jun 02;29(6):537–546. doi: 10.1080/13543784.2020.1764533
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Prats J, Deliargyris EN, et al. Pharmacokinetic and pharmacodynamic profile of a novel phospholipid aspirin formulation. Clin Pharmacokinet. 2022 Apr 01;61(4):465–479. doi: 10.1007/s40262-021-01090-2
   PubMed Web of Science ®Google Scholar